Google Play mobile download button
Apple IOS mobile download button
Google Play mobile download button
Apple IOS mobile download button
HomeBusiness: Oramed’s oral insulin pill fails; stock is down 72%

Balanced News: : Oramed’s oral insulin pill fails; stock is down 72%

Our 'quick read' news summary

Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed’s treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes. Oramed’s stock is down 10.7% for the past 12 months, while the broader S&P 500 SPX, +1.28% is down 15.7%.

Read different perspectives from these news sources

Searching for related articles, please check back here later!

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

More top reads from Balanced News Summary

Do you agree with this post's rating?
0
(0)
- Advertisment -
- Advertisment -